The state of Colorado currently has 12 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Denver, Aurora, Colorado Springs and Englewood.
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/13/2024
Locations: University of Colorado Anschutz Medical Campus - Department of Family Medicine, Aurora, Colorado +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
06/13/2024
Locations: University of Colorado Anschutz Medical Campus - Department of Family Medicine, Aurora, Colorado +1 locations
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
06/11/2024
Locations: University of Colorado, Aurora, Colorado +2 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
NCT05671835
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
06/06/2024
Locations: University of Colorado School of Medicine, Aurora, Colorado
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT04708782
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/04/2024
Locations: National Jewish Health, Denver, Colorado
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
NCT05483907
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
Gender:
All
Ages:
40 years and above
Trial Updated:
05/28/2024
Locations: National Jewish Health Main Campus, Denver, Colorado
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
NCT04482595
Recruiting
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge. Patients will be randomized 1:1 to receive BIO 300 or placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Pulmonary Fibrosis, COVID-19, Long COVID, Post-acute Respiratory Complications of COVID-19
Register for Updates
A Study to Investigate Leramistat in Patients With IPF
NCT05951296
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: National Jewish Health Main Campus, Denver, Colorado
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
The Genetics of Pulmonary Fibrosis
NCT03478553
Recruiting
This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/10/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Register for Updates
Advancing Prevention of Pulmonary Fibrosis
NCT04564183
Recruiting
This study plans to learn more about pulmonary fibrosis and how it develops. We want to determine if the disease can be detected early, before the lung is permanently scarred. This study will enroll participants who are not currently diagnosed with pulmonary fibrosis, but who have family members with pulmonary fibrosis. Because there is an increased risk within affected families, this cohort will allow us to learn how pulmonary fibrosis develops, and how the lungs change over time.
Gender:
All
Ages:
Between 40 years and 75 years
Trial Updated:
09/27/2023
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: IPF, Pulmonary Fibrosis, ILD
Register for Updates
A Study of Patients With Chronic Disease
NCT04263727
Recruiting
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared study infrastructure supports progressive development of the registry across the spectrum of chronic diseases.
Gender:
All
Ages:
All
Trial Updated:
08/24/2023
Locations: Asthma and Allergy Associates, PC, Colorado Springs, Colorado
Conditions: Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF, COPD, Respiratory Disease
Register for Updates
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)
NCT01088217
Recruiting
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis. Finding the genes that cause pulmonary fibrosis is the first step at developing better methods for early diagnosis and improved treatment for pulmonary fibrosis. The overall hypothesis is that inherited genetic factors predispose individuals to develop pulmonary fibrosis... Read More
Gender:
All
Ages:
All
Trial Updated:
09/11/2020
Locations: University of Colorado Denver, Aurora, Colorado +1 locations
Conditions: Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Familial Interstitial Pneumonia
Register for Updates